Technical Analysis for ALIM - Alimera Sciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 5.54 | -0.18% | -0.01 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Flat | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Fell Below 20 DMA | Bearish | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| 50 DMA Resistance | Bearish | -0.18% | |
| Crossed Above 20 DMA | Bullish | -0.18% | |
| Calm After Storm | Range Contraction | -0.18% | |
| NR7 | Range Contraction | -0.18% |
Get this analysis on your stocks daily!
- Earnings date: 10/24/2024
Alimera Sciences, Inc. Description
Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company's principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye to a placement site that takes advantage of the eye's natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME; and in Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is based in Alpharetta, Georgia.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Medicine Biopharmaceutical Disease Organ Systems Diabetes Eye Ophthalmic Macular Degeneration Diabetic Retinopathy Macular Edema Retina Veins Diabetic Macular Edema Blindness Age Related Macular Degeneration Fluid Dynamics Glucocorticoids Pivotal Corticosteroid Pregnanes Diketones Fluocinolone Retinal Vein Occlusion
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.65 |
| 52 Week Low | 2.6063 |
| Average Volume | 823,840 |
| 200-Day Moving Average | 4.18 |
| 50-Day Moving Average | 5.56 |
| 20-Day Moving Average | 5.54 |
| 10-Day Moving Average | 5.51 |
| Average True Range | 0.13 |
| RSI (14) | 52.61 |
| ADX | 43.58 |
| +DI | 19.60 |
| -DI | 58.04 |
| Chandelier Exit (Long, 3 ATRs) | 5.25 |
| Chandelier Exit (Short, 3 ATRs) | 4.70 |
| Upper Bollinger Bands | 5.71 |
| Lower Bollinger Band | 5.37 |
| Percent B (%b) | 0.49 |
| BandWidth | 6.07 |
| MACD Line | 0.01 |
| MACD Signal Line | 0.02 |
| MACD Histogram | -0.0162 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.59 | ||||
| Resistance 3 (R3) | 5.59 | 5.57 | 5.58 | ||
| Resistance 2 (R2) | 5.57 | 5.56 | 5.57 | 5.57 | |
| Resistance 1 (R1) | 5.56 | 5.55 | 5.55 | 5.56 | 5.57 |
| Pivot Point | 5.54 | 5.54 | 5.54 | 5.54 | 5.54 |
| Support 1 (S1) | 5.53 | 5.53 | 5.52 | 5.53 | 5.51 |
| Support 2 (S2) | 5.51 | 5.52 | 5.51 | 5.51 | |
| Support 3 (S3) | 5.50 | 5.51 | 5.50 | ||
| Support 4 (S4) | 5.50 |
